PFIZER INC.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2007-01-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 82
- Registration Number
- NCT00141414
- Locations
- π©πͺ
Pfizer Investigational Site, Bonn, Germany
To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2007-01-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 325
- Registration Number
- NCT00141245
- Locations
- π¬π§
Pfizer Investigational Site, York, United Kingdom
To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2007-01-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 750
- Registration Number
- NCT00141336
- Locations
- π¨π¦
Pfizer Investigational Site, Toronto, Ontario, Canada
CP-481,715 Nickel Allergy Study.
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2006-07-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 48
- Registration Number
- NCT00141180
- Locations
- π©π°
Pfizer Investigational Site, Hellerup, Denmark
Assessment of Onset, Safety & Toleration of UK-369,003 in Male Erectile Dysfunction
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2006-07-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 300
- Registration Number
- NCT00141349
- Locations
- πΊπΈ
Pfizer Investigational Site, Milwaukee, Wisconsin, United States
A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo for Smoking Cessation
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2010-09-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 250
- Registration Number
- NCT00141167
- Locations
- π¨π³
Pfizer Investigational Site, Taipei, Taiwan
Evaluation Of A Novel Methodology In The Assessment Of Urethral Function Using SS-RBX.
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2011-06-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT00141128
- Locations
- π©π°
Pfizer Investigational Site, Glostrup, Denmark
A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2016-01-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 74
- Registration Number
- NCT00141297
- Locations
- πΊπΈ
Karmanos Cancer Institute, Detroit, Michigan, United States
πΊπΈMemorial Sloan Kettering Cancer Center, New York, New York, United States
πΊπΈAbramson Cancer Center Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2009-11-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 455
- Registration Number
- NCT00141388
- Locations
- π¨π¦
Pfizer Investigational Site, Montreal, Quebec, Canada
To Evaluate Long-Term Safety and Efficacy of Pregabalin in the Treatment of Neuropathic Pain After Spinal Cord Injury.
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2008-01-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 132
- Registration Number
- NCT00141375
- Locations
- π¦πΊ
Pfizer Investigational Site, NSW, Australia
Β© Copyright 2024. All Rights Reserved by MedPath